Efficacy and safety of fluticasone and formoterol in a single pressurized metered dose inhaler

被引:48
作者
Bodzenta-Lukaszyk, Anna [1 ]
Pulka, Grazyna [2 ]
Dymek, Andrzej [3 ]
Bumbacea, Dragos [4 ]
McIver, Tammy [5 ]
Schwab, Birgit [6 ]
Mansikka, Heikki [5 ]
机构
[1] Med Univ Bialystok, Dept Allergol & Internal Med, PL-15276 Bialystok, Poland
[2] Dept Allergol & Internal Med ALL MED, Krakow, Poland
[3] Med Ctr Lucyna Andrzej Dymek, Strzelce Opolskie, Poland
[4] Carol Davila Univ Med & Pharm, Dept Pulmonol, Bucharest, Romania
[5] Mundipharma Res Ltd, Cambridge, England
[6] Mundipharma Res GmbH & Co KG, Limburg, Germany
关键词
Combination therapy; Asthma; Fluticasone; Formoterol; pMDI; flutiform (R); REAL-WORLD EVALUATION; ASTHMA INSIGHTS; AIRWAY; PROPIONATE; SALMETEROL; MANAGEMENT; DURATION; EUROPE; ADULTS;
D O I
10.1016/j.rmed.2010.11.011
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Background: Fluticasone and formoterol are well established medications for the treatment of asthma. This study (Clinicaltrials.gov identifier: NCT00734318) compares the efficacy and safety of a combination of these drugs in a single inhaler (fluticasone/formoterol) versus the individual components (fluticasone + formoterol). Methods: Patients aged >= 18 years (n = 620) with a history of severe, persistent reversible asthma for >= 6 months prior to screening were included in this randomized, double-blind study, which consisted of a screening phase of up to 5 days, a 2-week run-in phase and an 8-week treatment period. Results: Fluticasone/formoterol (500/20 mu g, b.i.d.) was at least as effective as fluticasone + formoterol (500 mu g + 24 mu g, b.i.d.) with respect to the primary outcome measure: there were similar increases in mean pre-morning dose forced expiratory volume in the first second (FEV1) in these two groups. Fluticasone/formoterol (500/20 mu g, b.i.d.) also demonstrated similar efficacy to fiuticasone + formoterol in terms of change in mean FEV1 from baseline pre-morning dose to 2 h post-morning dose at week 8, as well as for several secondary parameters. Fluticasone/formoterol (500/20 mu g, b.i.d.) demonstrated superiority to fluticasone monotherapy (500 mu g, b.i.d.) and fluticasone/formoterol (100/10 mu g, b.i.d.) for several secondary efficacy parameters. Fluticasone/formoterol had a similar safety and tolerability profile to fluticasone + formoterol. Conclusion: This study demonstrated that the fluticasone/formoterol combination is at least as effective as its components administered concurrently from separate inhalers. Fluticasone/formoterol (500/20 mu g, b.i.d.) showed superior efficacy to its inhaled corticosteroid component alone and the efficacy of fluticasone/formoterol was dose-dependent for several clinically important parameters. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:674 / 682
页数:9
相关论文
共 28 条
[1]
Poor control increases the economic cost of asthma - A multicentre population-based study [J].
Accordini, Simone ;
Bugiani, Massimiliano ;
Arossa, Walter ;
Gerzeli, Simone ;
Marinoni, Alessandra ;
Olivieri, Mario ;
Pirina, Pietro ;
Carrozzi, Laura ;
Dallari, Rossano ;
De Togni, Aldo ;
de Marco, Roberto .
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2006, 141 (02) :189-198
[2]
Adams NP, 2009, COCHRANE DB SYST REV
[3]
Adams NP, 2009, COCHRANE DB SYST REV
[4]
[Anonymous], 2009, Global Strategy for Asthma Management and Prevention
[6]
The costs of asthma [J].
Barnes, PJ ;
Jonsson, B ;
Klim, JB .
EUROPEAN RESPIRATORY JOURNAL, 1996, 9 (04) :636-642
[7]
A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer™) and placebo (pMDI or Aerolizer™) in asthmatic patients [J].
Bousquet, J ;
Huchon, G ;
Leclerc, V ;
Vicaut, E ;
Lefrançois, G .
RESPIRATION, 2005, 72 :6-12
[8]
Introduction -: Modulite®:: simplifying the changeover [J].
Bousquet, J .
RESPIRATORY MEDICINE, 2002, 96 :S1-S2
[9]
Asthma control in Europe:: A real-world evaluation based on an international population-based study [J].
Cazzoletti, Lucia ;
Marcon, Alessandro ;
Janson, Christer ;
Corsico, Angelo ;
Jarvis, Deborah ;
Pin, Isabelle ;
Accordini, Simone ;
Almar, Enrique ;
Bugiani, Massimiliano ;
Carolei, Adriana ;
Cerveri, Isa ;
Duran-Tauleria, Enric ;
Gislason, David ;
Gulsvik, Amund ;
Jogi, Rain ;
Marinoni, Alessandra ;
Martinez-Moratalla, Jesus ;
Vermeire, Paul ;
de Marco, Roberto .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2007, 120 (06) :1360-1367
[10]
Association between adherence with fixed dose combination fluticasone propionate/salmeterol on asthma outcomes and costs [J].
Delea, Thomas E. ;
Stanford, Richard H. ;
Hagiwara, May ;
Stempel, David A. .
CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (12) :3435-3442